Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 4 · newest first

  1. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remissionBlood · 2023
  2. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of conceptFrontiers in Immunology · 2023
  3. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agentsBlood Cancer Journal · 2023
  4. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsJournal of Clinical Oncology · 2023
  5. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAmerican Journal of Hematology · 2023
  6. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemiaBlood Advances · 2023
  7. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapiesHaematologica · 2023
  8. Phase II study of cladribine, idarubicin, and ara‐C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemiaAmerican Journal of Hematology · 2023
  9. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaBritish Journal of Haematology · 2023
  10. Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a reviewLeukemia & lymphoma/Leukemia and lymphoma · 2023
  11. S110: Phallcon: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Ph+ AllHemaSphere · 2023
  12. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib eraAmerican Journal of Hematology · 2023
  13. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaBlood · 2023
  14. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsJournal of Hematology & Oncology · 2023
  15. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisBlood Cancer Journal · 2023
  16. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progressAmerican Journal of Hematology · 2023
  17. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAmerican Journal of Hematology · 2023
  18. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyBlood Advances · 2023
  19. The role of therapy in the outcome of patients with myelofibrosisCancer · 2023
  20. Ultrasensitive NGS MRD assessment in Ph+  ALL : Prognostic impact and correlation with RT‐PCR for BCR::ABL1American Journal of Hematology · 2023
  21. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaJournal of Hematology & Oncology · 2023
  22. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class RearrangementsJCO Precision Oncology · 2023
  23. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantationBlood Advances · 2023
  24. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1 -Mutated Myeloid MalignanciesBlood Cancer Discovery · 2023
  25. Management of chronic myeloid leukemia in 2023 – common ground and common senseSHILAP Revista de lepidopterología · 2023
  26. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia2023
  27. Data from Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome2023
  28. Data from Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD222023
  29. Data from Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias2023
  30. Supplementary Figure Legends 1-6, Methods, Table 2 legend from Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia2023
  31. Supplementary Figure Legends 1-6, Methods, Table 2 legend from Role of Peroxisome Proliferator-Activated Receptor-γ and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia2023
  32. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Leukemia · 2023
  33. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)Haematologica · 2023
  34. Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly( ADP ‐ribose) polymerase proteins inhibitors for solid tumoursBritish Journal of Haematology · 2023
  35. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decadesJournal of Hematology & Oncology · 2023
  36. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaNature · 2023
  37. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyJournal of Clinical Oncology · 2023
  38. Association between bariatric surgery and outcomes in chronic myeloid leukemiaCancer · 2023
  39. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B‐cell acute lymphoblastic leukemiaCancer · 2023
  40. A global study for acute myeloid leukemia with RARG rearrangementBlood Advances · 2023
  41. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous LeukemiaMolecular Cancer Research · 2023
  42. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisHaematologica · 2023
  43. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemiaCancer · 2023
  44. The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR :: ABL1 tyrosine kinase inhibitorsAmerican Journal of Hematology · 2023
  45. Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangementsAmerican Journal of Hematology · 2023
  46. Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitorAmerican Journal of Hematology · 2023
  47. Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up resultsAmerican Journal of Hematology · 2023
  48. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomabTherapeutic Advances in Hematology · 2023
  49. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More YearsActa Haematologica · 2023
  50. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaTherapeutic Advances in Hematology · 2023